Regenxbio study shows similar clinical profile of eye drug produced via different methods

HDFC Bank rallies 7% in six days; stock inches towards all-time high Check Point Software announces $2B buyback (NASDAQ:CHKP)

Regenxbio (RGNX) on Saturday reported data from a phase 2 bridging study of RGX-314 for patients with wet age-related macular degeneration (wet AMD), a type of eye disorder.Regenxbio...

Source